Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Hong Kong Queen Mary Hospital
Hong Kong, Hong Kong, Hong Kong
David CL Lam, BSc,MBBS,PhD,FCCP,FACP,FRCP(E)Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Feb 2016
- Primary completion
- 31 Dec 2017
- Completion
- 31 Dec 2017
- Last update posted
- 27 Mar 2017
- Registered enrollment
- 100
- Registry id
- NCT03090815
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.